Chinese NMPA Accepts MAA Submission for ACCRUFeR®

AI SummaryClose X

Shield Therapeutics plc announced that its licensing partner, Beijing Aosaikang Pharmaceutical Co. Ltd, has had its Marketing Authorisation Application for ACCRUFeR® accepted by the Chinese National Medical Products Administration for the treatment of iron deficiency in adults. This submission is supported by data from the US FDA approval and a Phase 3 study in Chinese adults demonstrating clinically relevant efficacy and good tolerance, comparable to prior trials in other ethnicities. This development is significant as China's iron deficiency anemia therapy market is projected to grow substantially, presenting a considerable expansion opportunity for the company's oral iron treatment.

Disclaimer*

UK 100

Latest directors dealings